DDA Platform Releases In Vitro Permeability Assay to Evaluate Drug Permeability and Predict Drug Absorption

September 18 05:09 2021
DDA platform announced the release of its in vitro permeability assay to evaluate drug permeability and predict drug absorption.

New York, USA – September 17, 2021 – DDA platform, the professional division of Creative Bioarray, focuses on providing integrated drug discovery services to pharma, biotechnology companies, and academic institutions around the world. With the best screening equipment and cell models, as well as the latest innovations in drug discovery, DDA platform is committed to delivering first-class services to clients. Recently, DDA platform announced the release of its in vitro permeability assay to evaluate drug permeability and predict drug absorption.

Membrane permeability is a key feature that needs to be considered in the drug design process, especially when dealing with small molecules with intracellular targets, because the efficacy largely depends on their transmembrane ability. With decades of operating experience, Creative Bioarray is able to provide a wide range of analysis services based on permeability models, including predicting various permeation processes (pericellular, transcellular), and estimating different intracellular concentrations (membrane, cytoplasm, lysosome) , besides, evaluating the influence of experimental variation on the prediction results, and analyzing the measured in-vitro permeability data also included.

As part of the DDA Platform’s in vitro ADME screening service portfolio, the Caco-2 permeability test provides consistent, high-quality Caco-2 test data in a highly automated method. Available Caco-2 permeability test includes passive permeability in Caco-2, evaluation of MDR1 substrate in Caco-2, evaluation of BCRP substrate in Caco-2, and inhibition in Caco-2 (MDR1 and BCRP) Agent evaluation.

The MDCK permeability test provided by the DDA Platform can be used to determine intestinal or CNS permeability and study drug outflow to determine whether the target compound is suitable for oral administration or as a CNS therapeutic agent. DDA Platform provides cost-effective, consistent, high-quality data in a highly automated way, which helps to understand the mechanism of drug efflux and highlights potential problems with early drug penetration.

Parallel artificial membrane permeability measurement is a powerful tool for drug screening and has been widely used in drug research. With extensive experience in drug development, DDA platform has developed a variety of in vitro models and applied them to drug pharmacodynamics and pharmacokinetic studies.

“At present, establishing a suitable in vitro model has become an important direction for screening and evaluating drugs. DDA platform has extensive experience in drug development, and all absorption and permeability measurements provided can be used in standard human and animal model systems,” said Hannah Cole, the marketing director of Creative Bioarray, she also added, “We also provide comprehensive drug screening and evaluation services to meet your various needs for drug development and evaluation.”

About DDA platform

As a mature division of Creative Bioarray, DDA platform definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.

Media Contact
Company Name: Creative Bioarray
Contact Person: Hannah Cole
Email: Send Email
Phone: 1-631-386-8241
Country: United States
Website: https://dda.creative-bioarray.com